SG11202100369WA - Pharmaceutical dosage form which can be administered orally and has modified release - Google Patents
Pharmaceutical dosage form which can be administered orally and has modified releaseInfo
- Publication number
- SG11202100369WA SG11202100369WA SG11202100369WA SG11202100369WA SG11202100369WA SG 11202100369W A SG11202100369W A SG 11202100369WA SG 11202100369W A SG11202100369W A SG 11202100369WA SG 11202100369W A SG11202100369W A SG 11202100369WA SG 11202100369W A SG11202100369W A SG 11202100369WA
- Authority
- SG
- Singapore
- Prior art keywords
- dosage form
- administered orally
- pharmaceutical dosage
- modified release
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185127 | 2018-07-24 | ||
| US16/043,567 US10905667B2 (en) | 2018-07-24 | 2018-07-24 | Orally administrable modified-release pharmaceutical dosage form |
| PCT/EP2019/069561 WO2020020789A1 (en) | 2018-07-24 | 2019-07-19 | Pharmaceutical dosage form which can be administered orally and has modified release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100369WA true SG11202100369WA (en) | 2021-02-25 |
Family
ID=67314781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100369WA SG11202100369WA (en) | 2018-07-24 | 2019-07-19 | Pharmaceutical dosage form which can be administered orally and has modified release |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3826627B1 (en) |
| JP (1) | JP2021532113A (en) |
| KR (1) | KR20210035235A (en) |
| CN (1) | CN112469402B (en) |
| AU (1) | AU2019311234A1 (en) |
| BR (1) | BR112020026644A2 (en) |
| CA (1) | CA3107169A1 (en) |
| CL (1) | CL2021000160A1 (en) |
| CO (1) | CO2021000450A2 (en) |
| CR (1) | CR20210043A (en) |
| DO (1) | DOP2021000015A (en) |
| EC (1) | ECSP21003707A (en) |
| IL (1) | IL280083A (en) |
| JO (1) | JOP20210019A1 (en) |
| MA (1) | MA53368A (en) |
| MX (1) | MX2021000904A (en) |
| PE (1) | PE20210415A1 (en) |
| PH (1) | PH12021550170A1 (en) |
| SG (1) | SG11202100369WA (en) |
| TW (1) | TW202019402A (en) |
| UY (1) | UY38308A (en) |
| WO (1) | WO2020020789A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020245342A1 (en) | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
| CN112557533A (en) * | 2020-11-29 | 2021-03-26 | 北京康立生医药技术开发有限公司 | Analysis method of engletzin |
| TW202412753A (en) | 2022-06-09 | 2024-04-01 | 德商拜耳廠股份有限公司 | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| EP0277092B1 (en) | 1987-01-14 | 1992-01-29 | Ciba-Geigy Ag | Therapeutic system for slightly soluble active ingredients |
| DE19747261A1 (en) | 1997-10-25 | 1999-04-29 | Bayer Ag | Single-chamber osmotic pharmaceutical release system |
| DE19834044A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
| DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
| ATE433318T1 (en) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | OSMOTIC SYSTEM FOR ADMINISTRATION OF ACTIVE INGREDIENTS CONTAINING SOLID AMORPHOUS DISPERSIONS |
| AR031176A1 (en) | 2000-11-22 | 2003-09-10 | Bayer Ag | NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10220570A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
| DE102004062475A1 (en) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Solid, orally administrable, modified release pharmaceutical dosage forms |
| DE102008059206A1 (en) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic |
| DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
| CN103097387B (en) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | Pyrimidine and triazine that ring condenses and it is for treating and/or prevent the purposes of cardiovascular disease |
| DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
| DE102010043379A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use |
| DE102011007272A1 (en) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
| UY34856A (en) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | PHARMACEUTICAL PRESENTATION FORMS CONTAINING 5-CHLORO-N - ({(5S) -2-OXO-3- [4- (3-OXO-4- MORPHOLINYL) -PHENYL] -1,3-OXAZOLIDIN-5-IL} -METIL) -2-THIOFENCARBOXAMIDE |
| MX2020005646A (en) | 2017-12-01 | 2020-08-20 | Bayer Pharma AG | METHOD FOR PRODUCING (3<i>S</i>)-3-(4-CHLOR-3-{[(2<i>S,</i>3<i>R< /i>)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHE NYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT. |
-
2019
- 2019-07-19 MA MA053368A patent/MA53368A/en unknown
- 2019-07-19 JP JP2021503578A patent/JP2021532113A/en active Pending
- 2019-07-19 TW TW108125542A patent/TW202019402A/en unknown
- 2019-07-19 PE PE2021000084A patent/PE20210415A1/en unknown
- 2019-07-19 WO PCT/EP2019/069561 patent/WO2020020789A1/en unknown
- 2019-07-19 AU AU2019311234A patent/AU2019311234A1/en not_active Abandoned
- 2019-07-19 EP EP19740580.6A patent/EP3826627B1/en active Active
- 2019-07-19 MX MX2021000904A patent/MX2021000904A/en unknown
- 2019-07-19 JO JOP/2021/0019A patent/JOP20210019A1/en unknown
- 2019-07-19 CA CA3107169A patent/CA3107169A1/en active Pending
- 2019-07-19 BR BR112020026644-2A patent/BR112020026644A2/en not_active Application Discontinuation
- 2019-07-19 CR CR20210043A patent/CR20210043A/en unknown
- 2019-07-19 KR KR1020217004994A patent/KR20210035235A/en not_active Application Discontinuation
- 2019-07-19 SG SG11202100369WA patent/SG11202100369WA/en unknown
- 2019-07-19 CN CN201980049223.8A patent/CN112469402B/en active Active
- 2019-07-19 UY UY0001038308A patent/UY38308A/en not_active Application Discontinuation
-
2021
- 2021-01-11 IL IL280083A patent/IL280083A/en unknown
- 2021-01-18 EC ECSENADI20213707A patent/ECSP21003707A/en unknown
- 2021-01-19 CO CONC2021/0000450A patent/CO2021000450A2/en unknown
- 2021-01-20 CL CL2021000160A patent/CL2021000160A1/en unknown
- 2021-01-20 DO DO2021000015A patent/DOP2021000015A/en unknown
- 2021-01-22 PH PH12021550170A patent/PH12021550170A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY38308A (en) | 2020-02-28 |
| DOP2021000015A (en) | 2021-02-15 |
| ECSP21003707A (en) | 2021-02-26 |
| EP3826627A1 (en) | 2021-06-02 |
| MA53368A (en) | 2021-06-02 |
| PH12021550170A1 (en) | 2021-09-13 |
| TW202019402A (en) | 2020-06-01 |
| CA3107169A1 (en) | 2020-01-30 |
| AU2019311234A1 (en) | 2021-02-04 |
| CN112469402A (en) | 2021-03-09 |
| IL280083A (en) | 2021-03-01 |
| CR20210043A (en) | 2021-03-09 |
| JP2021532113A (en) | 2021-11-25 |
| EP3826627B1 (en) | 2023-10-18 |
| PE20210415A1 (en) | 2021-03-04 |
| JOP20210019A1 (en) | 2021-01-24 |
| WO2020020789A1 (en) | 2020-01-30 |
| BR112020026644A2 (en) | 2021-03-23 |
| MX2021000904A (en) | 2021-03-31 |
| KR20210035235A (en) | 2021-03-31 |
| CL2021000160A1 (en) | 2021-06-04 |
| CO2021000450A2 (en) | 2021-01-29 |
| CN112469402B (en) | 2024-05-14 |
| EP3826627C0 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258464A (en) | Pharmaceutical formulations for the oral delivery of peptide drugs | |
| IL280083A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| PL3487505T3 (en) | Administration and dosage of diaminophenothiazines | |
| IL304732A (en) | Modified release orally administered amino acid formulations | |
| HK1218884A1 (en) | Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity | |
| IL265970B (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| EP3400964A4 (en) | Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof | |
| EP3498280A4 (en) | Administration and dosage of therapeutic agent for endometriosis | |
| IL276323A (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| ZA201800470B (en) | An oral pharmaceutical dosage form for the delivery of a peptide and/or protein | |
| IL267219A (en) | Novel tebipenem pivoxil immediate and modified release oral dosage forms | |
| HK1245646A1 (en) | Pharmaceutical composition for oral administration | |
| IL273240A (en) | Oral-surface administered preparation for the prevention of illnesses acquired via the oral cavity and the pharynx | |
| IL261929B (en) | Stable pharmaceutical compositions for topical administration and uses thereof | |
| PL3326619T3 (en) | Solid oral pharmaceutical compositions comprising tenofovir and emtricitabine | |
| IL291196A (en) | Drug dosage determination devices and methods | |
| ZA202110948B (en) | Pharmaceutical dosage forms and methods for their production | |
| EP4052699A4 (en) | Orally administered solid dosage form drug | |
| SI3236950T1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
| SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
| EP3552632A4 (en) | Medicinal composition for treating and preventing chronic disease | |
| PL3277266T3 (en) | Oral solid dosage form of amlodipine and veterinary uses thereof | |
| EP3661486A4 (en) | Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof | |
| GB201710382D0 (en) | Administration and dosage of Diaminophenothiazines |